L-asparaginase: New about Well-Known Drug
https://doi.org/10.15690/pf.v18i3.2282
Abstract
The history of asparaginase clinical use is inextricably linked to the improvement of treatment programs for acute lymphoblastic leukaemia (ALL). Asparaginase, obtained from E. coli, has become the crucial part in the protocols for the treatment of ALL in children and adults since the 1960s-1970s due to its antitumor effect on lymphoid leukemia cells. Despite the evolution of therapeutic approaches in ALL management, changes in used chemotherapeutic agents, their administration regimens and doses, the asparaginase remains one of the leading therapeutic agents in ALL patients. With time ideas about the asparaginase mechanisms have expanded, new data have been accumulated on adverse effects (allergic reactions, thrombotic complications, pancreatitis, hepatic dysfunction, etc.). The asparaginase obtained from Erwinia chrysanthemi and PEGylated forms of the drug were used to reduce the frequency of any of such adverse effects. This literature review provides current concepts on the mechanism of L-asparaginase dosage forms action, describes side effects associated with the use of this medication. We also present our own clinical case of L-asparaginase (obtained from Erwinia chrysanthemi) administration in ALL patient with allergic reaction to PEG-L-asparaginase.
About the Authors
Yuliya S. Korkina
Russian Medical Academy of Continuing Professional Education
Russian Federation
Disclosure of interest:
Russian Federation
Korkina Yuliya Sergeevna, resident of the department of pediatric oncology.
125993, Moscow, Barrikadnaya Street, 2/1, b.1
Disclosure of interest:
Not declared
Timur T. Valiev
National Medical Research Center of Oncology named after N.N. Blokhin
Russian Federation
Disclosure of interest:
Russian Federation
Valiev Timur Teimurazovich - MD, PhD], Federal State Budgetary Institution N.N. Blokhin NMRCO.
24, Kashirskoe shosse, 115478, Moscow
Disclosure of interest:
Not declared
References
1. Batool T, Makky E, Jalal M, Yusoff M. A Comprehensive Review on L-Asparaginase and Its Applications. Appl Biochem Biotechnol. 2016;178(5):900-923. doi: 10.1007/s12010-015-1917-3
2. Cachumba J, Antunes F, Peres G, et al. Current applications and different approaches for microbial l-asparaginase production. Braz J Microbiol. 2016;47 (Suppl 1):77-85. doi: 10.1016/j.bjm.2016.10.004
3. Nguyen T, Do T, Nguyen T, Quen T. Expression, purification and evaluation of recombinant L-asparaginase in mehthylotrophic yeast Pichia pastoris. Journal of Vietnamese environment. 2014; 6(3):288-292. doi: 10.13141/jve.vol6.no3.pp288-292
4. Shrivastava A, Khan A, Khurshid M, et al. Recent developments in L-asparaginase discovery and its potential as anticancer agent. Crit Rev Oncol Hematol. 2016;100:1-10. doi: 10.1016/j.critrevonc.2015.01.002
5. Sokolov NN, Eldarov MA, Pokrovskaya MV, et al. Bacterial recombinant L-asparaginases: properties, structure and anti-prolifirative activity. Biomeditsinskaya khimiya. 2015;61(3):312-324. (In Russ). doi: 10.18097/PBMC20156103312
6. Baranova OYu. Oncaspar for the treatment of acute lymphoblastic leukemia. Clinical oncohematology. 2018;1(3):227-232. (In Russ).
7. Zhdanov D, Pokrovsky V, Pokrovskaya M, et al. Rhodospirillum rubruml-asparaginase targets tumor growth by a dual mechanism involving telomerase inhibition. Biochem Biophys Res Commun. 2017;492(2):282-288. doi: 10.1016/j.bbrc.2017.08.078
8. Patent N 2441914 Russian Federation, IPC C12N 9/82 (2006.01). Method for producing a substance of the recombinant L-asparaginase from Erwinia caroto-vora: N 2010140842/10: declare. 2010.10.06: publ. 2012.02.10. Karasev VS, Bochkova OP, Chugunov AM, et al. 8 p. (In Russ).
9. Alekseev NA. Gematologiya detsk-ogo vozrasta. St. Petersburg: Gippocrat; 1998. pp. 468-469. (In Russ).
10. Shervashidze M.A., Valiev T.T. Pediatric acute lymphoblastic leukemia treatment protocols improvement: emphasis on minimal residual disease. Oncogematologia = Oncohematology. 2020;15(3):12-26. (In Russ). doi: 10.17650/1818-8346-2020-15-3-12-26
11. Aleskerova GA. Lechenie detei s ostrym limfo-blastnym leikozom po programme ALL IC-BFM 2002. [dissertation]. Moscow; 2018. (In Russ).
12. Rumyantsev AG. Evolution of therapy for acute lymphoblastic leukemia in children: empirical, biological, and organizational aspects. Questions of hematology/oncology and immunopathology. 2015;14(1):5-15. (In Russ).
13. Van der Sluis I, Vrooman L, Pieters R, et al. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica. 2016;101(3):279-285. doi: 10.3324/haematol.2015.137380
14. Galstyan GM, Polevodova OA, Bazhenov AV, et al. Thrombotic and Hemorrhagic Complications in the Treatment of Acute Lymphoblastic Leukemia with L-Asparaginase. Clinical oncohematology. 2018;11(1):89-99. (In Russ). doi: 10.21320/2500-2139-2018-11-1-89-99
15. Koltsova E.M., Balandina A.N., Seregina E.A. et al. Modern aspects of the pathogenesis, diagnosis and therapy of hemostasis disorders in children with acute leukemias. The Russian Journal of Pediatric Hematology and Oncology. 2018;5(4):74-85. (In Russ). doi: 10.17650/2311-1267-2018-5-4-74-85
16. Dmitriev V, Lipay N, Migal N, et al. Thromboys in children with acute lyphoblastic leukemia. Haemotology. Tranfusiology. Eastern Medicine. 2017;3(3):365-375. (In Russ).
17. Losasso M, Bostrom B, Messinger Y. Retrospective cohort study monitoring PEG-asparaginase activity in acute lymphoblastic leukemia patients with and without premedication. F1000Res. 2019;8:1007. doi: 10.12688/f1000research.19298.2
18. Cooper S, Young D, Bowen C, et al. Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions. Pediatr Blood Cancer. 2019;66(8):e27797. doi: 10.1002/pbc.27797
19. Pieters R, Hunger S, Boos J, et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer. 2011;117(2):238-249. doi: 10.1002/cncr.25489
20. Salzer W, Bostrom B, Messinger Y, et al. Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia. Leuk Lymphoma. 2018;59(8):1797-1806. doi: 10.1080/10428194.2017.1386305
21. Rau R, Dreyer Z, Choi M, et al. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2018;65(3):e26873. doi: 10.1002/pbc.26873
22. Kloos R, van der Sluis I, Mastrobattista E, et al. Acute lymphoblastic leukaemia patients treated with PEGasparaginase develop antibodies to PEG and the succinate linker. Br J Haematol. 2020;189(3):442-451. doi: 10.1111/bjh.16254
23. Kloos R, Pieters R, Jumelet F, et al. Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia. J Clin Oncol. 2020;38(7):715-724. doi: 10.1200/JC0.19.02292
24. Tram Henriksen L, Gottschalk Hejfeldt S, Schmiegelow K, et al. Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation. Pediatr Blood Cancer. 2017;64(12):e26686. doi: 10.1002/pbc.26686
25. Lau KM, Saunders IM, Goodman A. Pegaspargase-induced hypertriglyceridemia in a patient with acute lymphoblastic leukemia. J Oncol Pharm Pract. 2020;26(1):193-199. doi: 10.1177/1078155219833438
26. Galindo R, Yoon J, Devoe C, Myers A. PEG-asparaginase induced severe hypertriglyceridemia. Arch Endocrinol Metab. 2016;60(2):173-177. doi: 10.1590/2359-3997000000068
27. Malbora B, Avci Z, Ozbek N. Treatment of severe hypertriglyceridemia associated with accidental pegylated asparaginase push in a child with relapsed acute lymphoblastic leukemia. Drug Chem Toxicol. 2012;35(4):463-466. doi: 10.3109/01480545.2011.640684
28. Thomas X, Le Jeune C. Erythrocyte encapsulated L-asparaginase (GRASPA) in acute leukemia. Int J Hematol Oncol. 2016;5(1):11-25. doi: 10.2217/ijh-2016-0002
29. Agrawal S, Kango N. Development and catalytic characterization of L-asparaginase nano-bioconjugates. Int J Biol Macromol. 2019;135:1142-1150. doi: 10.1016/j.ijbiomac.2019.05.154
30. Nunes JCF, Cristovao RO, Freire MG, et al. Recent Strategies and Applications for l-Asparaginase Confinement. Molecules. 2020;25(24):5827. doi: 10.3390/molecules25245827
31. FDA. Highlights of prescribing information Erwinaze (asparaginase Erwinia chrysanthemi). 2011.
32. Panetta J, Liu Y Swanson H, et al. Higher plasma asparaginase activity after intramuscular than intravenous Erwinia asparaginase. Pediatr Blood Cancer. 2020;67(7):e28244. doi: 10.1002/pbc.28244
33. Jazz Pharmaceuticals UK. ERWINASE (Erwinia L-asparaginase), 10,000 Units/vial, Lyophilisate for solution for injection. 2020.
34. Sassen S, Mathot R, Pieters R, et al. Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients. Haematologica. 2017;102(3):552-561. doi: 10.3324/haematol.2016.149195
Review
For citations:
Korkina Yu.S., Valiev T.T. L-asparaginase: New about Well-Known Drug. Pediatric pharmacology. 2021;18(3):227-232. (In Russ.) https://doi.org/10.15690/pf.v18i3.2282
Views:
1323
Email this article 